Pierre Michetti
TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update
Vulliemoz M, Brand S, Juillerat P, Mottet C, Ben-Horin S, Michetti P, on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update. Digestion 2020; 101 Suppl 1:16-26.
Jul 31, 2020TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update
Jul 31, 2020Digestion 2020; 101 Suppl 1:16-26
Vulliemoz Marianne, Brand Stephan, Juillerat Pascal, Mottet Christian, Ben-Horin Shomron, Michetti Pierre, on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology
Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know
Schreiner P, Rogler G, Juillerat P, Vavricka S, Vulliemoz M, Restellini S, Schoepfer A, Michetti P, Brand S, Maillard M, Fehr J, Mueller N, Biedermann L. Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know. J Crohns Colitis 2020
Jun 27, 2020Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know
Jun 27, 2020J Crohns Colitis 2020
Schreiner Philipp, Rogler Gerhard, Juillerat Pascal, Vavricka Stephan R, Vulliemoz Marianne, Restellini Sophie, Schoepfer Alain, Michetti Pierre, Brand Stephan, Maillard Michel H, Fehr Jan, Mueller Nicolas J, Biedermann Luc
Treatment Algorithms for Crohn's Disease
Sulz M, Burri E, Michetti P, Rogler G, Peyrin-Biroulet L, Seibold F, on behalf of the Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Treatment Algorithms for Crohn's Disease. Digestion 2020; 101 Suppl 1:43-57.
Mar 13, 2020Treatment Algorithms for Crohn's Disease
Mar 13, 2020Digestion 2020; 101 Suppl 1:43-57
Sulz Michael, Burri Emanuel, Michetti Pierre, Rogler Gerhard, Peyrin-Biroulet Laurent, Seibold Frank, on behalf of the Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology
Publisher Correction: Microbial network disturbances in relapsing refractory Crohn's disease
Yilmaz B, Stelling J, Wiest R, Swiss IBD Cohort Investigators, Rogler G, Maillard M, Pittet V, Geuking M, Mueller C, Michetti P, Fournier N, Franc Y, Bravo F, Ramon C, Øyås O, Juillerat P, Macpherson A. Publisher Correction: Microbial network disturbances in relapsing refractory Crohn's disease. Nat Med 2019; 25:701.
Apr 1, 2019Publisher Correction: Microbial network disturbances in relapsing refractory Crohn's disease
Apr 1, 2019Nat Med 2019; 25:701
Yilmaz Bahtiyar, Stelling Jörg, Wiest Reiner, Swiss IBD Cohort Investigators, Rogler Gerhard, Maillard Michel H, Pittet Valerie E H, Geuking Markus, Mueller Christoph, Michetti Pierre, Fournier Nicolas, Franc Yannick, Bravo Francisco Damian, Ramon Charlotte, Øyås Ove, Juillerat Pascal, Macpherson Andrew J
Microbial network disturbances in relapsing refractory Crohn's disease
Yilmaz B, Stelling J, Wiest R, Swiss IBD Cohort Investigators, Rogler G, Maillard M, Pittet V, Geuking M, Mueller C, Michetti P, Fournier N, Franc Y, Bravo F, Ramon C, Øyås O, Juillerat P, Macpherson A. Microbial network disturbances in relapsing refractory Crohn's disease. Nat Med 2019; 25:323-336.
Jan 21, 2019Microbial network disturbances in relapsing refractory Crohn's disease
Jan 21, 2019Nat Med 2019; 25:323-336
Yilmaz Bahtiyar, Stelling Jörg, Wiest Reiner, Swiss IBD Cohort Investigators, Rogler Gerhard, Maillard Michel H, Pittet Valerie E H, Geuking Markus, Mueller Christoph, Michetti Pierre, Fournier Nicolas, Franc Yannick, Bravo Francisco Damian, Ramon Charlotte, Øyås Ove, Juillerat Pascal, Macpherson Andrew J
Cohort Profile Update: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS)
Pittet V, Michetti P, Mueller C, Braegger C, von Känel R, Schoepfer A, Macpherson A, Rogler G, Swiss IBD Cohort Study Group. Cohort Profile Update: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). Int J Epidemiol 2019; 48:385-386f.
Jan 1, 2019Cohort Profile Update: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS)
Jan 1, 2019Int J Epidemiol 2019; 48:385-386f
Pittet Valérie, Michetti Pierre, Mueller Christoph, Braegger Christian P, von Känel Roland, Schoepfer Alain, Macpherson Andrew J, Rogler Gerhard, Swiss IBD Cohort Study Group
Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals
Pittet V, Maillard M, Simonson T, Fournier N, Rogler G, Michetti P, Swiss IBD Cohort Study Group(∗). Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals. Clin Gastroenterol Hepatol 2018; 17:2050-2059.e1.
Nov 22, 2018Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals
Nov 22, 2018Clin Gastroenterol Hepatol 2018; 17:2050-2059.e1
Pittet Valerie E H, Maillard Michel H, Simonson Thomas, Fournier Nicolas, Rogler Gerhard, Michetti Pierre, Swiss IBD Cohort Study Group(∗)
Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey
Vavricka S, Biedermann L, Michetti P, Straumann A, Misselwitz B, Scharl M, Manser C, Greuter T, Zeitz J, Frei P, Borovicka J, Seibold F, Schoepfer A, Rogler G, Spasojevic M. Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey. Dig Dis 2017; 35:423-432.
Jun 9, 2017Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey
Jun 9, 2017Dig Dis 2017; 35:423-432
Vavricka Stephan R, Biedermann Luc, Michetti Pierre, Straumann Alex, Misselwitz Benjamin, Scharl Michael, Manser Christine, Greuter Thomas, Zeitz Jonas, Frei Pascal, Borovicka Jan, Seibold Frank, Schoepfer Alain M, Rogler Gerhard, Spasojevic Milos
Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study
Vavricka S, Misselwitz B, Scharl M, Heinrich H, Manser C, Safroneeva E, Raja Ali R, Rogler G, Schoepfer A, Greuter T, Zeitz J, Biedermann L, Juillerat P, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. Inflamm Bowel Dis 2017
Apr 27, 2017Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study
Apr 27, 2017Inflamm Bowel Dis 2017
Vavricka Stephan R, Misselwitz Benjamin, Scharl Michael, Heinrich Henriette, Manser Christine N, Safroneeva Ekaterina, Raja Ali Raja Affendi, Rogler Gerhard, Schoepfer Alain M, Greuter Thomas, Zeitz Jonas, Biedermann Luc, Juillerat Pascal, Gubler Martin, Gantenbein Claudine, Spoerri Muriel, Froehlich Florian, Seibold Frank, Protic Marijana, Michetti Pierre, Straumann Alex, Fournier Nicolas
Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey
Vavricka S, Michetti P, Straumann A, Seibold F, Scharl M, Sauter B, de Saussure P, Rogler G, Manz M, Geyer M, Felley C, Binek J, Bansky G, Schoepfer A, for the Swiss IBDnet. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflamm Bowel Dis 2010
Dec 22, 2010Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey
Dec 22, 2010Inflamm Bowel Dis 2010
Vavricka Stephan R, Michetti Pierre, Straumann Alex, Seibold Frank, Scharl Michael, Sauter Bernhard, de Saussure Philippe, Rogler Gerhard, Manz Michael, Geyer Martin, Felley Christian, Binek Janek, Bansky Georg, Schoepfer Alain M, for the Swiss IBDnet
Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey
Schoepfer A, Straumann A, Seibold F, Sauter B, de Saussure P, Rogler G, Manz M, Geyer M, Felley C, Binek J, Vavricka S, Michetti P. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey. Inflammatory bowel diseases 2009
Dec 10, 2009Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey
Dec 10, 2009Inflammatory bowel diseases 2009
Schoepfer Alain M, Straumann Alex, Seibold Frank, Sauter Bernhard, de Saussure Philippe, Rogler Gerhard, Manz Michael, Geyer Martin, Felley Christian, Binek Janek, Vavricka Stephan R, Michetti Pierre